Fig. 7

Lack of significant differences in selected lymphocyte subsets stratified for patients with and without secondary autoimmunity during the 48-month study period. Each row represents data from one lymphocyte subset, with the left panels in each row illustrating between-subjects analyses, followed by within-subjects analyses for patients with secondary autoimmunity (middle panels) and without secondary autoimmunity (right panels) disease activity. a–c Changes in CD4+CD25+CD127+foxP3- Teff. d–f Changes in CD4+CD25^hiCD127^lo/neg foxP3+ Tregs. g–i Changes in CD19+CD20+CD27- total naïve B cells. j–l Changes in CD19+CD20+CD27-CD24^hi CD38^hi B cells. m–o Changes in CD3-CD56^bright NK cells. p–r Changes in CD3+CD56+ NKT cells. Data represent median/IQR; closed symbols indicate patients with secondary autoimmunity, and open symbols indicate patients without secondary autoimmunity. Differences over time between and within groups were not statistically significant (linear mixed effects model for repeated measures)